Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)

PHASE3RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Capecitabine

Metronomic capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Fujian Medical University Union Hospital

OTHER

collaborator

Guangzhou Panyu Central Hospital

OTHER

collaborator

The Central Hospital of Yongzhou

UNKNOWN

collaborator

The First People's Hospital of Huaihua

UNKNOWN

collaborator

Hanzhong Central Hospital

OTHER

collaborator

Yichang Central People's Hospital

OTHER

collaborator

Affiliated Hospital of Guangdong Medical University

OTHER

collaborator

Jiangmen Central Hospital

OTHER

collaborator

Xiang Yang No.1 Peoples Hospital

UNKNOWN

lead

Sun Yat-sen University

OTHER